Review
Oncology
Andrew B. Barbour, Simon Kirste, Anca-Liga Grosu, Shankar Siva, Alexander V. Louie, Hiroshi Onishi, Anand Swaminath, Bin S. Teh, Sarah P. Psutka, Emily S. Weg, Jonathan J. J. Chen, Jing Zeng, John L. Gore, Evan Hall, Jay J. J. Liao, Rohann J. M. Correa, Simon S. Lo
Summary: Patients with localized renal cell carcinoma often have medical comorbidities limiting their surgical candidacy, thus necessitating less invasive treatment options. Stereotactic ablative radiotherapy has emerged as a safe and effective management option with a growing body of evidence supporting its use. This article discusses recent advances in the use of stereotactic ablation radiotherapy for localized renal cell carcinoma, while guiding providers on practical points for patient selection and clinical application.
Article
Oncology
Yang Liu, Zhiling Zhang, Ruiqi Liu, Wensu Wei, Zitong Zhang, Lixin Mai, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He, Pei Dong
Summary: The study showed that adding stereotactic body radiotherapy (SBRT) to non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) therapy in metastatic renal cell carcinoma patients significantly prolonged overall survival (OS). The addition of SBRT improved OS in patients with clear-cell histology and a longer duration of response to first-line antiangiogenic therapy, with similar rates of grade >= 3 toxicities between the two treatment groups.
RADIATION ONCOLOGY
(2021)
Article
Urology & Nephrology
Shankar Siva, Mathias Bressel, Simon T. Wood, Mark G. Shaw, Sherene Loi, Shahneen K. Sandhu, Ben Tran, Arun A. Azad, Jeremy H. Lewin, Katharine E. Cuff, Howard Y. Liu, Daniel Moon, Jeremy Goad, Lih-Ming Wong, Michael LimJoon, Jennifer Mooi, Sarat Chander, Declan G. Murphy, Nathan Lawrentschuk, David Pryor
Summary: The RAPPORT trial investigated the combination of high-dose precision radiotherapy and a short course of immunotherapy in patients with low-volume metastatic kidney cancer. The results showed that this treatment regimen was well tolerated, with excellent cancer control in known disease sites, and a proportion of patients were free from cancer relapse in the longer term. These findings are encouraging and warrant further investigation.
Article
Oncology
Martin Schmitt, Lucie Aussenac, Joseph Seitlinger, Veronique Lindner, Georges Noel, Delphine Antoni
Summary: Stereotactic radiotherapy is a viable alternative for patients with localised stage non-small-cell lung carcinoma who are inoperable or refuse surgery. The microscopic tumour extension varies according to histological type, with different adapted margins needed for squamous cell carcinoma and adenocarcinoma. Multivariate analysis showed a significant relationship between maximum microextension distance, size, and shrinkage coefficient.
Article
Biochemistry & Molecular Biology
Dalia Kaakour, Steven Seyedin, Roozbeh Houshyar, Nataliya Mar
Summary: In this case report, a male patient with penile squamous cell carcinoma achieved a complete durable treatment response using pembrolizumab and stereotactic body radiation therapy, despite having genomic features of an immunologically cold tumor. This case highlights the importance of investigating treatment options for tumors that lack genomic features susceptible to immunotherapy.
Article
Oncology
Thomas B. Brunner, Dominik Bettinger, Michael Schultheiss, Lars Maruschke, Lukas Sturm, Nico Bartl, Ivana Koundurdjieva, Simon Kirste, Hannes P. Neeff, Christian Goetz, Nils Henrik Nicolay, Gabriele Ihorst, Fabian Bamberg, Robert Thimme, Anca-Ligia Grosu, Eleni Gkika
Summary: The study findings indicate that SBRT is an effective and well-tolerated local treatment for patients with hepatocellular carcinoma, providing high rates of local control and maintaining quality of life for patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Urology & Nephrology
Muhammad Ali, Jennifer Mooi, Nathan Lawrentschuk, Rana R. Mckay, Raquibul Hannan, Simon S. Lo, William A. Hall, Shankar Siva
Summary: Stereotactic ablative body radiotherapy (SABR) is a promising treatment modality for primary and metastatic renal cell carcinoma (RCC), offering potential benefits in terms of local control and delaying systemic therapy. It can be safely combined with systemic therapy and provides palliation for brain and spinal metastases.
Article
Oncology
Pablo Munoz-Schuffenegger, Aisling Barry, Eshetu G. Atenafu, John Kim, James Brierley, Jolie Ringash, Anthony Brade, Robert Dinniwell, Rebecca K. S. Wong, Charles Cho, Tae Kyoung Kim, Gonzalo Sapisochin, Laura A. Dawson
Summary: This study investigated the long-term outcomes of patients with HCC and MVI treated with SBRT, showing promising results in terms of local control and overall survival. Patients who received sorafenib treatment after SBRT had longer survival, but some patients experienced adverse events like gastrointestinal bleeding.
RADIOTHERAPY AND ONCOLOGY
(2021)
Letter
Oncology
Wee Loon Ong, Shankar Siva, Roger L. Milne, Farshad Foroudi, Jeremy L. Millar
Summary: This letter to the editor adds to the limited literature on the trend in the use of stereotactic radiation therapy for metastatic renal cell carcinoma.
Article
Oncology
Isaure Roquette, Emilie Bogart, Thomas Lacornerie, Massih Ningarhari, Jean-Emmanuel Bibault, Marie-Cecile Le Deley, Eric F. Lartigau, David Pasquier, Xavier Mirabel
Summary: This study describes the treatment efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC). The analysis of data from 318 patients showed that SBRT is efficient for the management of HCC with a favorable toxicity profile.
Article
Oncology
Karam Khaddour, Alice Zhou, Omar Butt, Jiayi Huang, George Ansstas
Summary: Oligometastatic progression poses challenges for the management and diagnosis of tumor diseases, and circulating-tumor DNA may aid in diagnosis and disease monitoring. This report highlights the potential role of stereotactic body radiation therapy in addressing oligometastatic progression through the description of two cases.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Nicolas Magne, Nicolas Milhade, Paul Sargos, Wafa Bouleftour
Summary: This study aims to gather the current literature on therapeutic approaches and management of oligometastatic renal cell carcinoma. Two recent stereotactic body radiotherapy (SBRT) studies have shown promising outcomes, either alone or in combination with antineoplastic drugs, for oligometastatic renal cell carcinoma. However, many unresolved questions remain, and further phase III clinical trials are urgently needed to validate the findings and improve patient care. Additionally, interdisciplinary discussions are essential to determine the best arrangement between systemic and focal treatments for optimal patient benefit.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Oncology
Ming-Wei Ma, Hong-Zhen Li, Xian-Shu Gao, Ming-Zhu Liu, Huan Yin, Kai-Wei Yang, Jia-Yan Chen, Xue-Ying Ren, Dian Wang
Summary: This retrospective study investigated the efficacy and prognostic factors of high-dose SABR for oligometastatic RCC patients. The results showed that high-dose SABR had a certain efficacy in this patient population, and patients with a short time interval between radiation therapy and those who received radiation therapy before tyrosine kinase inhibitor (TKI) failure had a better survival period.
Article
Oncology
Marie Cantaloube, Florence Castan, Morgane Creoff, Jessica Prunaretty, Karl Bordeau, Morgan Michalet, Eric Assenat, Boris Guiu, Georges-Philippe Pageaux, Marc Ychou, Norbert Ailleres, Pascal Fenoglietto, David Azria, Olivier Riou
Summary: The study demonstrates that stereotactic body radiation therapy (SBRT) using volumetric modulated arc therapy (VMAT) and real-time adaptive tumor gating for hepatocellular carcinoma (HCC) is effective with optimal local control and low toxicity, especially in patients not eligible for other local therapies. Additionally, the diameter of lesions and the volume of PTV were found to be associated with disease-free survival and overall survival in HCC patients receiving SBRT with VMAT.
Article
Oncology
Leah M. Katz, Victor Ng, S. Peter Wu, Sherry Yan, David Grew, Samuel Shin, Nicholas W. Colangelo, Allison McCarthy, Harvey I. Pass, Abraham Chachoua, Peter B. Schiff
Summary: This study retrospectively analyzed the efficacy and safety of lung stereotactic body radiation therapy (SBRT) in 60 non-small cell lung cancer (NSCLC) patients. The results showed that SBRT achieved similar survival rates and progression-free survival rates in patients with early stage, locally recurrent, and oligoprogressive disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Christian C. Okoye, Ravi B. Patel, Shaakir Hasan, Tarun Podder, Anton Khouri, Jeffrey Fabien, Yuxia Zhang, Donald Dobbins, Jason W. Sohn, Jiankui Yuan, Min Yao, Mitchell Machtay, Andrew E. Sloan, Jonathan Miller, Simon S. Lo
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2016)
Article
Medicine, Research & Experimental
Christina E. Franke, Anna E. Czapar, Ravi B. Patel, Nicole F. Steinmetz
MOLECULAR PHARMACEUTICS
(2018)
Article
Oncology
Lauryn R. Werner, Jasdeep S. Kler, Monica M. Gressett, Maureen Riegert, Lindsey K. Werner, Clinton M. Heinze, Joseph G. Kern, Mahyar Abbariki, Amy K. Erbe, Ravi B. Patel, Raghava N. Sriramaneni, Paul M. Harari, Zachary S. Morris
RADIOTHERAPY AND ONCOLOGY
(2017)
Review
Oncology
Ravi B. Patel, Claire C. Baniel, Raghava N. Sriramaneni, Kristin Bradley, Stephanie Markovina, Zachary S. Morris
Editorial Material
Clinical Neurology
Christian C. Okoye, Ravi B. Patel, Arjun Sahgal, Eric L. Chang, Simon S. Lo
Article
Radiology, Nuclear Medicine & Medical Imaging
Joseph J. Grudzinski, Reinier Hernandez, Ian Marsh, Ravi B. Patel, Eduardo Aluicio-Sarduy, Jon Engle, Zachary Morris, Bryan Bednarz, Jamey Weichert
JOURNAL OF NUCLEAR MEDICINE
(2019)
Article
Chemistry, Multidisciplinary
Ravi B. Patel, Mingzhou Ye, Peter M. Carlson, Abigail Jaquish, Luke Zangl, Ben Ma, Yuyuan Wang, Ian Arthur, Ruosen Xie, Ryan J. Brown, Xing Wang, Raghava Sriramaneni, KyungMann Kim, Shaoqin Gong, Zachary S. Morris
ADVANCED MATERIALS
(2019)
Article
Oncology
Peter M. Carlson, Manasi Mohan, Matthew Rodriguez, Vladimir Subbotin, Claire X. Sun, Ravi B. Patel, Jen Birstler, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Zachary S. Morris, Amy K. Erbe, Paul M. Sondel
Summary: This study found that differences in depth of tumor implantation can lead to variations in response to immunotherapy. The mobile or fixed characteristics of tumors may predict response to therapy, regardless of intended implantation depth. This suggests that physical examination of tumor characteristics can ensure consistent tumor depth for immunotherapy experiments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Peter M. Carlson, Manasi Mohan, Ravi B. Patel, Jen Birstler, Lauren Nettenstrom, Dagna Sheerar, Kathryn Fox, Matthew Rodriguez, Anna Hoefges, Reinier Hernandez, Chris Zahm, KyungMann Kim, Douglas G. McNeel, Jamey Weichert, Zachary S. Morris, Paul M. Sondel
Summary: Most shared resource flow cytometry facilities do not allow analysis of radioactive samples. Researchers are investigating a low-dose molecular targeted radionuclide therapy as an immunomodulator and need a reliable method for cryopreserving immune samples for flow cytometry analysis. Evaluating different fixation and cryopreservation protocols, it was found that freezing samples after all staining and fixation are completed most accurately matches noncryopreserved results.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Cell Biology
Ravi B. Patel, Reinier Hernandez, Peter Carlson, Joseph Grudzinski, Amber M. Bates, Justin C. Jagodinsky, Amy Erbe, Ian R. Marsh, Ian Arthur, Eduardo Aluicio-Sarduy, Raghava N. Sriramaneni, Won Jong Jin, Christopher Massey, Alexander L. Rakhmilevich, David Vail, Johnathan W. Engle, Trang Le, Kyung Mann Kim, Bryan Bednarz, Paul M. Sondel, Jamey Weichert, Zachary S. Morris
Summary: The study demonstrates that delivering radiation semiselectively to tumors through targeted radionuclide therapy (TRT) can enhance response to immune checkpoint inhibitors (ICIs), leading to therapeutic efficacy and tumor-specific T cell memory in murine models. Combination of TRT and ICI activates production of proinflammatory cytokines, promotes tumor infiltration by CD8(+) T cells, and reduces metastases, suggesting a promising approach to improve response to ICIs for various tumor types.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Alexander A. Pieper, Alexander L. Rakhmilevich, Daniel Spiegelman, Ravi B. Patel, Jen Birstler, Won Jong Jin, Peter M. Carlson, Deborah H. Charych, Jacquelyn A. Hank, Amy K. Erbe, Willem W. Overwijk, Zachary S. Morris, Paul M. Sondel
Summary: The combination of local RT and BEMPEG showed a cooperative antitumor effect in multiple immunologically 'cold' tumor models, along with increased IL-2 receptor expression on peripheral T cells. Adding immune checkpoint blockade to RT+BEMPEG further strengthened the antitumor response in some models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Michael C. Bellavia, Ravi B. Patel, Carolyn J. Anderson
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care, but many patients with poorly immunogenic tumors fail to benefit. External beam radiotherapy (EBRT) has been shown to synergize with ICI to prompt remarkable tumor regression and even eradication, but is not suitable for widely disseminated disease. Targeted radiopharmaceutical therapy (TRT) selectively delivers radiation to both the primary tumor and the metastatic sites, and has shown promising results, leading to regulatory approval of certain agents.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Oncology
Peter M. Carlson, Ravi B. Patel, Jen Birstler, Matthew Rodriquez, Claire Sun, Amy K. Erbe, Amber M. Bates, Ian Marsh, Joseph Grudzinski, Reinier Hernandez, Alexander A. Pieper, Arika S. Feils, Alexander L. Rakhmilevich, Jamey P. Weichert, Bryan P. Bednarz, Paul M. Sondel, Zachary S. Morris
Summary: The combination of external beam radiation therapy (EBRT) and intratumoral immunocytokine (IC) generates an effective in situ vaccine (ISV) against GD2-positive murine tumors. However, ISV does not produce an adequate response against distant tumors. Additional radiation therapy (RT) to all sites of disease may augment the antitumor responses to ISV.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biology
Reinier Hernandez, Kirsti L. Walker, Joseph J. Grudzinski, Eduardo Aluicio-Sarduy, Ravi Patel, Christopher D. Zahm, Anatoly N. Pinchuk, Christopher F. Massey, Ariana N. Bitton, Ryan J. Brown, Paul M. Sondel, Zachary S. Morris, Jonathan W. Engle, Christian M. Capitini, Jamey P. Weichert
COMMUNICATIONS BIOLOGY
(2019)
Article
Chemistry, Multidisciplinary
Ravi Patel, Anna E. Czapar, Steven Fiering, Nancy L. Oleinick, Nicole F. Steinmetz
Article
Oncology
Derek A. Mumaw, Allison J. Hazy, Aleksander Vayntraub, Thomas J. Quinn, Kamran Salari, John H. Chang, Noah Kalman, Sanford Katz, James Urbanic, Robert H. Press, Arpi Thukral, Henry Tsai, George E. Laramore, Jason Molitoris, Carlos Vargas, Samir H. Patel, Craig Stevens, Rohan L. Deraniyagala
Summary: This study evaluated contralateral recurrences in patients with oropharyngeal squamous cell carcinoma who received unilateral proton beam therapy. The results showed a favorable contralateral neck failure rate that was comparable to photon irradiation.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn
Summary: This study suggests that hypofractionated radiation therapy alone is a feasible option for early stage esophageal squamous cell carcinoma patients. Particularly, in patients with tumor length < 3 cm, this treatment scheme shows favorable local control rates with low incidence of esophageal toxicities.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang
Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yiwei Yang, Jianxin Wang, Feng Gao, Zhen Liu, Tangzhi Dai, Haowen Zhang, Hongyu Zhu, Tingting Wang, Dexin Xiao, Kui Zhou, Zheng Zhou, Dai Wu, Xiaobo Du, Sen Bai
Summary: This paper provides a comprehensive description of the current status of PARTER, which is the first experimental FLASH platform utilizing megavoltage X-rays. It showcases the reliable performance and stability of the dosimeters and monitors used in PARTER, as well as the satisfactory dose distribution and characteristics of the FLASH X-rays. The platform effectively meets the requirements of preclinical research on megavoltage X-ray FLASH and undergoes continuous upgrades.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B. Simone Ii, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Rimner
Summary: The purpose of this study was to identify predictors of disease progression in early-stage non-small cell lung cancer (NSCLC) patients after receiving definitive stereotactic body radiation therapy (SBRT). The results showed that tumor diameter and SUVmax were the most frequently reported features associated with progression/survival, and a re-fitted model including these two features had the best performance.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yong-Qiao He, Tong-Min Wang, Da-Wei Yang, Wen-Qiong Xue, Chang-Mi Deng, Dan-Hua Li, Wen-Li Zhang, Ying Liao, Ruo-Wen Xiao, Lu-Ting Luo, Hua Diao, Xia-Ting Tong, Yan-Xia Wu, Xue-Yin Chen, Jiang-Bo Zhang, Ting Zhou, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Shao-Dan Zhang, Ye-Zhu Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Wei-Hua Jia
Summary: In this study, researchers aimed to establish a predictive model for radiation-induced brain injury (RBI) in nasopharyngeal carcinoma (NPC) patients by incorporating clinical factors and newly developed genetic variants. They conducted a large-scale retrospective study and a genome-wide association study to develop a polygenic risk score (PRS) for RBI risk prediction. The results showed that the PRS, combined with clinical factors, improved the accuracy of RBI risk stratification and suggested personalized radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2024)
Review
Oncology
Xiaoyong Xiang, Zhe Ji, Jing Jin
Summary: A review of studies suggests that brachytherapy as a salvage therapy for recurrent glioblastoma shows acceptable safety and good post-treatment clinical efficacy for selected patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
M. Berbee, C. T. Muijs, F. E. M. Voncken, L. Wee, M. Sosef, B. van Etten, J. W. van Sandick, F. A. R. M. Warmerdam, J. J. de Haan, E. Oldehinkel, J. M. van Dieren, L. Boersma, J. A. Langendijk, A. van der Schaaf, J. B. Reitsma, E. Schuit
Summary: This study externally validated a model for predicting 2-year total mortality in lung cancer patients in esophageal cancer patients. The intercept and/or slope of the original model needed adjustment to achieve good performance in esophageal cancer patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominique Reijtenbagh, Jeremy Godart, Joan Penninkhof, Sandra Quint, Andras Zolnay, Jan-Willem Mens, Mischa Hoogeman
Summary: This study compared the performance of the current PotD strategy with non-adaptive and fully online-adaptive techniques in the treatment of cervical cancer patients. The findings show that the PotD protocol is effective in improving normal tissue sparing compared to no adaptation, while fully online-adaptive approaches can further reduce target volume but come with a more complex workflow.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Albrecht Weiss, Steffen Loeck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G. C. Troost
Summary: Traditional models for predicting radiation pneumonitis may not be applicable to non-small cell lung cancer patients treated with passively-scattered proton therapy. The use of effective alpha/beta parameter can predict the occurrence of radiation pneumonitis in these patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Z. A. R. Gouw, J. Jeong, A. Rimner, N. Y. Lee, A. Jackson, A. Fu, J-j. Sonke, J. O. Deasy
Summary: This study investigates the effectiveness of non-uniform fractionation schedules in radiotherapy for early-stage non-small cell lung cancer. Through modeling, optimized schedules are proposed to minimize local failures and toxicity risk. The results suggest that non-standard primer shot fractionation can reduce hypoxia-induced radioresistance and improve treatment outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Sara Ronchi, Alessandro Cicchetti, Maria Bonora, Rossana Ingargiola, Anna Maria Camarda, Stefania Russo, Sara Imparato, Paolo Castelnuovo, Ernesto Pasquini, Piero Nicolai, Mohssen Ansarin, Michele Del Vecchio, Marco Benazzo, Ester Orlandi, Barbara Vischioni
Summary: This study evaluates the efficacy and toxicity of carbon ion radiotherapy (CIRT) in locally advanced head and neck mucosal melanoma patients. The results show that CIRT is safe and effective in treating the local region, and immunotherapy after relapse can improve overall survival. However, further prospective trials are needed to assess the role of targeted/immune- systemic therapy in this disease.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominik Wawrzuta, Justyna Klejdysz, Marzanna Chojnacka
Summary: This study analyzed articles about radiation oncology published in The New York Times since its inception in 1851, and identified changes in media sentiment and prevalent themes related to radiotherapy. The findings suggest an increasing negative sentiment in media coverage towards radiotherapy, with a shift towards reporting treatment errors, toxicity, and ineffectiveness.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin
Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Fabio L. Cury, Gustavo A. Viani, Andre G. Gouveia, Camila V. S. Freire, Gabriel de A. Grisi, Fabio Y. Moraes
Summary: In limb-sparing treatment of soft tissue sarcoma patients, a 5-day course of preoperative radiotherapy results in high local control and favorable R0 margins, with acceptable complication rates, particularly for patients receiving higher biological equivalent doses.
RADIOTHERAPY AND ONCOLOGY
(2024)